America and Britain Announce No-Tariff Pact on Prescription Drugs.

The UK and US have concluded a landmark trade agreement that will preserve no tariffs on British pharmaceutical exports going into the US market.

Agreement Details of the Deal

As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the NHS. This commitment secures that import taxes on these vital products will remain at zero for a period of three years.

This deal follows recent warnings to dramatically increase import taxes on branded drug imports, with potential rates discussed reaching 100%.

"This arrangement between the UK reinforces the global environment for new treatments and brings much-needed balance to American-British drug exports," a release said.

Commercial Impact

Medicines are one of the UK's largest exports to the America, which is by far the biggest market for major companies like GSK and AstraZeneca.

Trade data reveal that in the year prior to September, the UK shipped drugs valued at over eleven billion pounds to the US. This value represented nearly one-fifth of all goods exports in that period.

"This guarantee protects employment, increases investment and facilitates the UK to become a worldwide center for biotech and pharma," a minister stated.

Detailed UK Commitments

The deal includes several specific pledges from the UK:

• Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new medicines to be prohibitively costly by 25%.
• Increased NHS Spending: There is a target to increase overall NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
• Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. Previously, refunds topped twenty percent.

Industry Background

The pact follows a long-running tension between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.

This friction were heightened by assertions that US consumers were charged significantly more for the same drugs than consumers in the other developed nations.

Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while major investments have been directed toward US facilities.

One official acknowledged that the NHS must invest a greater share on treatments, noting that its spending on drugs had shrunk as a percentage of its resources over the previous ten-year period.